Literature DB >> 21445644

Long-term results of tailored D(2) lymph node dissection after R(0) surgery for gastric cancer.

Marco Catarci1, Leonardo Antonio Montemurro, Sabrina Ghinassi, Antonio Di Cintio, Leonardo Leone, Luigi Marino Cosentino, Maria Antonietta Viarengo, Giovanni Battista Grassi.   

Abstract

Implementation of extended lymph node dissection for gastric cancer in western non-specialized centers through tailoring its extent upon disease stage and patient comorbidities was suggested as a wise policy to reduce morbidity and mortality rates, albeit with a potential for undertreatment in elderly and/or comorbid patients. Current definition of R(0) resection for gastric cancer lacks consideration of treatment-related variables such as extended lymph node dissection. Few studies to date have tried to fill this gap in such a clinical context. A retrospective evaluation of factors influencing long-term results after R(0) surgery was done in a prospective series of a non-specialized western surgical unit during the implementation of D(2) lymphadenectomy. Univariate and multivariate analysis of 22 variables were performed on a prospective database of 233 consecutive R(0) resections performed by ten different surgeons in 10 years. Endpoint was disease-free survival calculated at 5 and at 10 years. Disease-free survival rates were independently influenced by age, American Society of Anesthesiologists (ASA) status and lymph node ratio. Subset analysis of the status at censor stratified for age and ASA status failed to identify any significant difference in disease recurrence rates. Lymph node ratio was the only treatment-related independent prognostic factor for long-term results after R(0) surgery for gastric cancer in the setting of a non-specialized western unit, where the extent of lymph node dissection needs to be tailored on the presence of comorbidities (ASA status).

Entities:  

Mesh:

Year:  2011        PMID: 21445644     DOI: 10.1007/s13304-011-0065-8

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  39 in total

1.  Comparison of prognostic significance of nodal staging between old (4th edition) and new (5th edition) UICC TNM classification for gastric carcinoma. International Union Against Cancer.

Authors:  C H Yoo; S H Noh; Y I Kim; J S Min
Journal:  World J Surg       Date:  1999-05       Impact factor: 3.352

2.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

3.  Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program.

Authors:  E Bollschweiler; K Boettcher; A H Hoelscher; M Sasako; T Kinoshita; K Maruyama; J R Siewert
Journal:  Br J Surg       Date:  1992-02       Impact factor: 6.939

4.  Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients.

Authors:  G H Kampschöer; K Maruyama; C J van de Velde; M Sasako; T Kinoshita; K Okabayashi
Journal:  Br J Surg       Date:  1989-09       Impact factor: 6.939

5.  Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial.

Authors:  K C M J Peeters; S A Hundahl; E Klein Kranenbarg; H Hartgrink; C J H van de Velde
Journal:  World J Surg       Date:  2005-12       Impact factor: 3.352

6.  Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma.

Authors:  Michael W Kattan; Martin S Karpeh; Madhu Mazumdar; Murray F Brennan
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

7.  Gastric cancer surgery--a balance of risk and radicality.

Authors:  Peter Lamb; T Sivashanmugam; Martin White; Mark Irving; John Wayman; Simon Raimes
Journal:  Ann R Coll Surg Engl       Date:  2008-04       Impact factor: 1.891

8.  Indexes of surgical quality in gastric cancer surgery: experience of an Italian network.

Authors:  G Verlato; F Roviello; A Marchet; S Giacopuzzi; D Marrelli; D Nitti; G de Manzoni
Journal:  Ann Surg Oncol       Date:  2009-01-01       Impact factor: 5.344

9.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

10.  Clinical implications of metastatic lymph node ratio in gastric cancer.

Authors:  Caigang Liu; Ping Lu; Yang Lu; Huimian Xu; Shubao Wang; Junqing Chen
Journal:  BMC Cancer       Date:  2007-10-24       Impact factor: 4.430

View more
  4 in total

1.  The pattern of lymph node metastasis and the suitability of 7th UICC N stage in predicting prognosis of remnant gastric cancer.

Authors:  Fangxuan Li; Rupeng Zhang; Han Liang; Hui Liu; Jichuan Quan; Jingzhu Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-03       Impact factor: 4.553

2.  Effect of complication grade on survival following curative gastrectomy for carcinoma.

Authors:  Nan Jiang; Jing-Yu Deng; Xue-Wei Ding; Li Zhang; Hong-Gen Liu; Yue-Xiang Liang; Han Liang
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

3.  Prognostic value of tumor size in patients with remnant gastric cancer: is the seventh UICC stage sufficient for predicting prognosis?

Authors:  Jun Lu; Chang-ming Huang; Chao-hui Zheng; Ping Li; Jian-wei Xie; Jia-bin Wang; Jian-xian Lin; Qi-yue Chen; Long-long Cao; Mi Lin
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

4.  Pancreatic enzyme supplementation after gastrectomy for gastric cancer: a randomized controlled trial.

Authors:  Marco Catarci; Manuele Berlanda; Giovanni Battista Grassi; Francesco Masedu; Stefano Guadagni
Journal:  Gastric Cancer       Date:  2017-08-14       Impact factor: 7.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.